Clinical Trial

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on…

8 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people…

8 months ago

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data availableMARLBOROUGH, Mass., April 24, 2025…

8 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

April 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be…

8 months ago

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

ADC assay now available through ABS; customer study proves IO60 is a spatial workhorseMARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE)…

8 months ago

ORYZON Raises €30 Million in Capital Increase

Issued 12,765,958 new sharesPriced at €2.35 per share, representing a 15.44% discount on the 5-day VWAPStrong investor demand, with the…

8 months ago

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company…

8 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patientTreatment…

8 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

8 months ago

Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round

Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study. Capital raised to date…

8 months ago